News | February 06, 2007

Siemens Opens Doors to Imaging Biomarkers for Oncology, Neurology

February 7, 2007 - Siemens Medical Solutions today opened the doors to a new molecular imaging biomarker research site, Siemens Medical Solutions Molecular Imaging (MI) Biomarker Research facility, as Siemens strives to become the world's first full-service diagnostics company, integrating in vivo and in vitro imaging diagnostics capabilities.
At the new facility, researchers will be dedicated exclusively to the development of molecular imaging biomarkers. The goal of the research is to spur the growth of in vivo molecular diagnostics, in which in vivo diagnostic tools are designed to identify debilitating diseases such as cancer and neurological diseases at their earliest stages. The biomarkers bind to the diseased cells or tissues and cause them to "light up" when scanned using PET-CT (Positron Emission Tomography-Computed Tomography) or SPECT-CT (Single-Photon Emission Computed Tomography).
Siemens' goal is to bring several new agents to the market over the next 5 - 10 years. Research and development efforts conducted at the facility will focus
largely on oncology and neurology, and also include other areas such
as inflammation and microfluidics/nanotechnology research.

"Molecular medicine is heralding a new era in diagnostic capabilities that could change the lives of millions of Americans, and Siemens is helping lead the field out of the research lab and into practical use," said Michael Reitermann, president, Molecular Imaging division, Siemens Medical Solutions. "Advancing this field brings with it the promise of personalized therapeutics, which would not only improve the efficiency of health care, but most importantly, would also improve the quality of health care for patients."
The opening of the site is the latest step for the company in becoming Siemens recently launched Siemens Medical Solutions Diagnostics as the in vitro complement to the portfolio on the heels of acquisitions of Bayer Diagnostics and Los Angeles-based Diagnostic Products Corporation.

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...